Literature DB >> 9779379

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection.

T M File1, J S Tan, J F Plouffe.   

Abstract

Infections caused by M. pneumoniae, C. pneumoniae, and Legionella spp. are important causes of community-acquired pneumonia (CAP). In the past decade, considerable new information has come to light concerning these organisms. Despite this, debate continues concerning the syndromic approach to CAP and the scientific merit of lumping these pathogens together. Because the etiologic diagnosis of these pathogens is established only in a minority of cases, the true prevalence tends to be underestimated. In clinical practice, these pathogens are often empirically treated. More rapid and cost-effective diagnostic techniques are needed so that the clinical course of patients with these infections can be better characterized.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779379     DOI: 10.1016/s0891-5520(05)70199-9

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  29 in total

1.  Rapid-cycle PCR for detection and typing of Mycoplasma pneumoniae in clinical specimens.

Authors:  F Kong; S Gordon; G L Gilbert
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

2.  Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.

Authors:  G Hoeffken; D Talan; L S Larsen; S Peloquin; S H Choudhri; D Haverstock; P Jackson; D Church
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

Review 3.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

4.  Acute pneumonia and systemic lupus erythematosus.

Authors:  M V Sun; P J Kaplan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

5.  Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy.

Authors:  A. Saito; Fumio Miki; Kotaro Oizumi; Naoto Rikitomi; Akira Watanabe; Hironobu Koga; Yoshito Niki; Nobuchika Kusano
Journal:  J Infect Chemother       Date:  1999-06       Impact factor: 2.211

6.  Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome.

Authors:  Louise K Francois Watkins; Daniel Olson; Maureen H Diaz; Xia Lin; Alicia Demirjian; Alvaro J Benitez; Jonas M Winchell; Christine C Robinson; Kirk A Bol; Mary P Glodé; Samuel R Dominguez; Lisa A Miller; Preeta K Kutty
Journal:  Pediatr Infect Dis J       Date:  2017-06       Impact factor: 2.129

7.  Reactive species mediate inhibition of alveolar type II sodium transport during mycoplasma infection.

Authors:  Judy M Hickman-Davis; Carmel McNicholas-Bevensee; Ian C Davis; He-Ping Ma; Glenda C Davis; Charles A Bosworth; Sadis Matalon
Journal:  Am J Respir Crit Care Med       Date:  2005-10-27       Impact factor: 21.405

8.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

9.  Mycoplasma pneumonia: Clinical features and management.

Authors:  Surender Kashyap; Malay Sarkar
Journal:  Lung India       Date:  2010-04

Review 10.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.